Sachiyo Minegishi

Sachiyo Minegishi is the Chief Financial Officer at Kriya Therapeutics. Prior to Rectify, Ms. Minegishi was the Chief Financial Officer at Akouos (acquired by Eli Lilly), and before this led cross-functional global development of a portfolio of gene therapies for Sickle Cell Disease at bluebird bio. Earlier in her career, Ms. Minegishi held leadership roles at Aegerion, Human Genome Sciences, Genzyme and Amgen, after beginning her career in investment banking at Merrill Lynch. Ms. Minegishi earned a B.S. in Chemical Engineering and Economics from the Massachusetts Institute of Technology and an M.B.A. from the Wharton School of the University of Pennsylvania.